ArticleBMJ open2026
Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSkin rash is the most common adverse effect in patients with cancer receiving epidermal growth factor receptor inhibitors (EGFRIs), which can impair quality of life and lead to treatment discontinuation. Numerous primary studies have explored factors that may predict the development of skin rash. However, the wide range of variables and substantial heterogeneity among these studies limit the availability of high-quality, synthesised evidence. A comprehensive scoping review is therefore warranted to systematically map and synthesise the risk factors for EGFRI-induced skin rash in patients with cancer. METHODS AND ANALYSIS: This scoping review will be conducted following the Joanna Briggs Institute methodology and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. An initial search strategy was developed and piloted in PubMed. The comprehensive search will include PubMed, Embase, Web of Science Core Collection, CINAHL Ultimate, CENTRAL (Cochrane Central Register of Controlled Trials), SinoMed, CNKI (China National Knowledge Infrastructure) and Wanfang Database. Grey literature sources, including ProQuest Dissertations & Theses Global, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform, will also be searched. All searches were conducted from database inception to 30 January 2026, restricted to human studies published in English or Chinese. All original quantitative studies, including cohort, case-control and cross-sectional designs, will be eligible for inclusion. Two independent reviewers will screen studies for eligibility, extract relevant data and assess study quality. Any discrepancies will be resolved through discussion or consultation with a third reviewer. Results will be presented in tabular and/or graphical formats, accompanied by a descriptive summary of the risk factors for EGFRI-induced skin rash. ETHICS AND DISSEMINATION: This scoping review will rely exclusively on the collection and analysis of published and/or publicly available sources; therefore, ethical approval is not required. The findings will be disseminated through publication in peer-reviewed journals, presentation at scientific conferences and via digital science communication platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.